Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03485963 · ClinicalTrials.gov registry record · Phase 1

HIV-1 Specific T -Cells (HST-NEETs) for HIV-Infected Individuals

A Phase 1 study of HIV Infections, sponsored by Catherine Bollard.

Completed
Registry status
Phase 1
Development phase
7
Enrollment target
3
Study locations

NCT03485963: Completed Phase 1 study of HIV Infections, sponsored by Catherine Bollard.

NCT03485963 is a Phase 1 study of HIV Infections that has completed, run by Catherine Bollard. The registered enrollment target is 7 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03485963, a Phase 1 study of HIV Infections, has completed, sponsored by Catherine Bollard.

COMPLETED
Registry status
Phase 1
Development phase
7 participants
Enrollment target
3
Study locations

Study Summary

This is a phase I, multi-site, study of the safety, immunologic and virologic responses of ex vivo expanded HIV-1 multi-antigen specific T-cell therapy (HST-NEET) as a therapeutic strategy in HIV-infected individuals suppressed on antiretroviral therapy (ART).

Primary Outcome

Occurrence of any ≥ Grade 3 AE including signs/symptoms, lab toxicities, and/or clinical events, that is possibly, probably or definitely related to study treatment any time from the first day of study treatment until 28 days after the last infusion. Safety data will include local and systemic signs and symptoms, laboratory measures of safety/toxicity, and all adverse and serious adverse events. Safety data will be routinely collected throughout the duration of the study. Relationship to study t

Conditions Studied

HIV Infections

Interventions

  • BIOLOGICAL HST-NEETs

Study Locations (3)

District of Columbia

  • Whitman Walker Health Research Department (Wwh) - Washington D.C.
  • Children's National Hospital - Washington D.C.
  • Children's National Medical Center and WHITMAN WALKER HEALTH RESEARCH DEPARTMENT (WWH) - Washington D.C.

Trial Details

FieldValue
Enrollment Target 7 participants
Start Date 2019-03-21
Est. Completion 2022-06-21
Phase Phase 1
Catherine Bollard

14 total trials

What the finished NCT03485963 record still lists

NCT03485963 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (98% lower).

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which HST-NEETs is the first listed.

NCT03485963 reports a single indexed study location in District of Columbia.

Frequently Asked Questions

What is clinical trial NCT03485963 about?

NCT03485963 is a clinical study titled "HIV-1 Specific T -Cells (HST-NEETs) for HIV-Infected Individuals". This is a phase I, multi-site, study of the safety, immunologic and virologic responses of ex vivo expanded HIV-1 multi-antigen specific T-cell therapy (HST-NEET) as a therapeutic strategy in HIV-infected individuals suppressed on antiretroviral therapy (ART).

What is the current status of trial NCT03485963?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2019-03-21. Estimated completion is 2022-06-21.

What conditions does trial NCT03485963 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT03485963?

The interventions under investigation include: HST-NEETs (BIOLOGICAL).

Who is sponsoring clinical trial NCT03485963?

This trial is sponsored by Catherine Bollard, which has 14 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03485963 being conducted?

This trial has 3 study locations across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03485963's enrollment target sits among peer trials

7 536th of 542 higher than 6 of 542 other HIV Infections trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03485963, the US trial registry maintained by the National Library of Medicine. NCT03485963 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.